Zheng Quan Shi Bao Wang·2025-09-30 00:53Core Viewpoint - Lunan Pharmaceutical has submitted its application to the Hong Kong Stock Exchange, with CICC as its sole sponsor, focusing on the discovery, development, and commercialization of radiopharmaceuticals for cancer diagnosis and treatment [1] Company Overview - Lunan Pharmaceutical, established in 2021, specializes in radiopharmaceuticals for oncology, with a pipeline of 13 candidate drugs, including 7 diagnostic and 6 therapeutic radiopharmaceuticals [1] - Key products include diagnostic radiopharmaceuticals 18F-LNC1001 and 18F-LNC1005 for prostate cancer, as well as therapeutic drug 177Lu-LNC1011 [1] Market Potential - The global prostate cancer drug market is projected to grow from $19.3 billion in 2024 to $32.4 billion by 2030, indicating significant growth opportunities for the company [1] Commercialization Strategy - The company plans to initiate commercialization in top-tier hospitals in first-tier cities in China, with plans for gradual expansion [1] Production Capacity - Lunan Pharmaceutical is constructing a new cGMP-compliant production facility, expected to be completed in Q1 2026, with a maximum annual production capacity of 7.674×10^14 Bq [1]